{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:30:41Z","timestamp":1787671841572,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ymgme.2026.109876","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:34:24Z","timestamp":1772728464000},"page":"109876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and validation of a clinical severity score for long-chain fatty acid oxidation disorders using Real-World-Evidence from Canada"],"prefix":"10.1016","volume":"148","author":[{"given":"Randa","family":"Sultan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Salvarinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailly","family":"Jain-Ghai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Vockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadet","family":"Mercimek-Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ymgme.2026.109876_bb0005","doi-asserted-by":"crossref","first-page":"108","DOI":"10.17925\/EE.2021.17.2.108","article-title":"Diagnosis and clinical management of long-chain fatty-acid oxidation disorders: a review","volume":"17","author":"Baker","year":"2021","journal-title":"touchREV. Endocrinol."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109876_bb0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.pcl.2017.11.006","article-title":"Inborn errors of metabolism with myopathy: defects of fatty acid oxidation and the carnitine shuttle system","volume":"65","author":"El-Gharbawy","year":"2018","journal-title":"Pediatr. Clin. N. Am."},{"issue":"Suppl. 3","key":"10.1016\/j.ymgme.2026.109876_bb0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000448321","article-title":"Primary carnitine deficiency and newborn screening for disorders of the carnitine cycle","volume":"68","author":"Longo","year":"2016","journal-title":"Ann. Nutr. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2026.109876_bb0020","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10545-010-9090-x","article-title":"Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening","volume":"33","author":"Spiekerkoetter","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2026.109876_bb0025","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/jimd.12371","article-title":"New insights into carnitine-acylcarnitine translocase deficiency from 23 cases: management challenges and potential therapeutic approaches","volume":"44","author":"Ryder","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.109876_bb0030","first-page":"47","article-title":"Clinical, biochemical, and molecular features in 37 Saudi patients with very long chain acyl CoA dehydrogenase deficiency","volume":"40","author":"Obaid","year":"2018","journal-title":"JIMD Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109876_bb0035","article-title":"Biochemical and genetic characteristics of patients with primary carnitine deficiency identified through newborn screening","volume":"16","author":"Lin","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109876_bb0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10545-016-0004-4","article-title":"Long-term outcome of expanded newborn screening at Boston children\u2019s hospital: benefits and challenges in defining true disease","volume":"40","author":"Landau","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2026.109876_bb0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ymgme.2017.06.015","article-title":"Biochemical characteristics of newborns with carnitine transporter defect identified by newborn screening in California","volume":"122","author":"Gallant","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"37","key":"10.1016\/j.ymgme.2026.109876_bb0050","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021944","article-title":"Neonatal-onset multiple acyl-CoA dehydrogenase deficiency (MADD) in the ETFDH gene: a case report and a literature review","volume":"99","author":"Ding","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ymgme.2026.109876_bb0055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1542\/peds.109.1.99","article-title":"Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients","volume":"109","author":"den Boer","year":"2002","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.ymgme.2026.109876_bb0060","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/jimd.12075","article-title":"Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes","volume":"42","author":"Bleeker","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2026.109876_bb0065","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41436-020-01070-0","article-title":"Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders","volume":"23","author":"Marsden","year":"2021","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109876_bb0070","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpn.2015.10.009","article-title":"Peripheral neuropathy in patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency - a follow-up EMG study of 12 patients","volume":"20","author":"Immonen","year":"2016","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"5","key":"10.1016\/j.ymgme.2026.109876_bb0075","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10545-017-0041-7","article-title":"Carnitine palmitoyltransferase 1A deficiency: abnormal muscle biopsy findings in a child presenting with Reye\u2019s syndrome","volume":"40","author":"Bellusci","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2026.109876_bb0080","doi-asserted-by":"crossref","first-page":"313","DOI":"10.12997\/jla.2020.9.3.313","article-title":"Mitochondrial fatty acid oxidation disorders: laboratory diagnosis, pathogenesis, and the complicated route to treatment","volume":"9","author":"Wanders","year":"2020","journal-title":"J. Lipid Atheroscler."},{"issue":"4","key":"10.1016\/j.ymgme.2026.109876_bb0085","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s10545-009-1125-9","article-title":"Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop","volume":"32","author":"Spiekerkoetter","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2026.109876_bb0090","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10545-010-9188-1","article-title":"Current issues regarding treatment of mitochondrial fatty acid oxidation disorders","volume":"33","author":"Spiekerkoetter","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7 Suppl","key":"10.1016\/j.ymgme.2026.109876_bb0095","first-page":"S147","article-title":"Long-chain fatty acid oxidation disorders and current management strategies","volume":"26","author":"Vockley","year":"2020","journal-title":"Am. J. Manag. Care"},{"issue":"2","key":"10.1016\/j.ymgme.2026.109876_bb0100","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ymgme.2022.04.001","article-title":"Response to triheptanoin therapy in critically ill patients with LC-FAOD: report of patients treated through an expanded access program","volume":"136","author":"Vockley","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109876_bb0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jimd.12313","article-title":"Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: results from an open-label, long-term extension study","volume":"44","author":"Vockley","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.109876_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.598760","article-title":"Physiological perspectives on the use of Triheptanoin as Anaplerotic therapy for long chain fatty acid oxidation disorders","volume":"11","author":"Sklirou","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.ymgme.2026.109876_bb0115","series-title":"Framework for FDA\u2019s Real-world Evidence Program. [https:\/\/www.fda.gov\/media\/120060\/download]","author":"U.S. Food and Drug Administration","year":"2018"},{"issue":"8","key":"10.1016\/j.ymgme.2026.109876_bb0120","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am. J. Epidemiol."},{"issue":"15","key":"10.1016\/j.ymgme.2026.109876_bb0125","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2217\/cer-2020-0161","article-title":"Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions","volume":"9","author":"Sheffield","year":"2020","journal-title":"J Comp Eff Res."},{"issue":"4","key":"10.1016\/j.ymgme.2026.109876_bb0130","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10545-011-9325-5","article-title":"Nijmegen paediatric CDG rating scale: a novel tool to assess disease progression","volume":"34","author":"Achouitar","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"issue":"12","key":"10.1016\/j.ymgme.2026.109876_bb0135","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.nmd.2006.08.006","article-title":"A scale to monitor progression and treatment of mitochondrial disease in children","volume":"16","author":"Phoenix","year":"2006","journal-title":"Neuromuscul. Disord."},{"issue":"5","key":"10.1016\/j.ymgme.2026.109876_bb0140","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/jimd.12635","article-title":"Establishment and validation of a clinical severity scoring system for succinic semialdehyde dehydrogenase deficiency","volume":"46","author":"Tokatly Latzer","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.109876_bb0145","article-title":"Efficacy results from a 12-month double-blind randomized trial of arimoclomol for treatment of Niemann-pick disease type C (NPC): presenting a rescored 4-domain NPC clinical severity scale","volume":"43","author":"Mengel","year":"2025","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2026.109876_bb0150","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/mds.22231","article-title":"A novel global assessment scale for Wilson\u2019s disease (GAS for WD)","volume":"24","author":"Aggarwal","year":"2009","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.ymgme.2026.109876_bb0155","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/01.wnl.0000234852.43688.bf","article-title":"GAMT deficiency: features, treatment, and outcome in an inborn error of creatine synthesis","volume":"67","author":"Mercimek-Mahmutoglu","year":"2006","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ymgme.2026.109876_bb0160","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s10545-007-0595-x","article-title":"A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease","volume":"30","author":"Davies","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2026.109876_bb0165","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/jimd.12753","article-title":"International validation of meaningfulness of postural sway and gait to assess myeloneuropathy in adults with adrenoleukodystrophy","volume":"47","author":"Yska","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"issue":"12","key":"10.1016\/j.ymgme.2026.109876_bb0170","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/gim.2015.22","article-title":"Fatty acid oxidation flux predicts the clinical severity of VLCAD deficiency","volume":"17","author":"Diekman","year":"2015","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109876_bb0175","first-page":"181","article-title":"Very long-chain acyl-CoA dehydrogenase deficiency in a Swedish cohort: clinical symptoms, newborn screening, enzyme activity, and genetics","volume":"63","author":"Olsson","year":"2022","journal-title":"JIMD Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2026.109876_bb0180","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"ACMG laboratory quality assurance committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"issue":"7616","key":"10.1016\/j.ymgme.2026.109876_bb0185","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","article-title":"Exome aggregation consortium. Analysis of protein-coding genetic variation in 60,706 humans","volume":"536","author":"Lek","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ymgme.2026.109876_bb0190","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/13816810.2024.2303682","article-title":"A proposal for an updated staging system for LCHADD retinopathy","volume":"45","author":"Wongchaisuwat","year":"2024","journal-title":"Ophthalmic Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109876_bb0195","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J. Chiropr. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2026.109876_bb0200","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109876_bb0205","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-022-02512-5","article-title":"Outcomes of mitochondrial long chain fatty acid oxidation and carnitine defects from a single center metabolic genetics clinic","volume":"17","author":"Ambrose","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109876_bb0210","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-024-03437-x","article-title":"Genetic landscape of primary mitochondrial diseases in children and adults using molecular genetics and genomic investigations of mitochondrial and nuclear genome","volume":"19","author":"Ambrose","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"issue":"12","key":"10.1016\/j.ymgme.2026.109876_bb0215","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1212\/01.wnl.0000219759.72195.41","article-title":"Mitochondrial disease in adults: a scale to monitor progression and treatment","volume":"66","author":"Schaefer","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ymgme.2026.109876_bb0220","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226001599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226001599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:59:00Z","timestamp":1787669940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719226001599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1096719226001599"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.109876","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a clinical severity score for long-chain fatty acid oxidation disorders using Real-World-Evidence from Canada","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.109876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109876"}}